Literature DB >> 19651759

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan.

Josep Redon1, Maria Jose Fabia.   

Abstract

A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there are differences between agents in terms of antihypertensive efficacy and 24-hour blood pressure control.This review assesses the data comparing olmesartan with other ARBs in terms of blood pressure reductions, goal achievement, 24-hour control and speed of onset. Olmesartan seems to have a more favourable efficacy profile relative to standard doses of the ARBs used in comparative studies; results consistent with the high degree of blockade of the angiotensin II type 1 receptor for olmesartan.Taken together, there might be differences between ARBs regarding their blood pressure lowering efficacy, and these results may provide further support of the benefits of olmesartan therapy since choice of an effective agent is crucial in antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651759     DOI: 10.1177/1470320309342735

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  7 in total

1.  Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.

Authors:  Tomoko Ishizuka; Izumi Fujimori; Mitsunori Kato; Chisa Noji-Sakikawa; Motoko Saito; Yasushi Yoshigae; Kazuishi Kubota; Atsushi Kurihara; Takashi Izumi; Toshihiko Ikeda; Osamu Okazaki
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

Review 2.  Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.

Authors:  Francesco Vittorio Costa
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-07-10

Review 3.  Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.

Authors:  Massimo Volpe; Caterina Santolamazza; Vittoria Mastromarino; Roberta Coluccia; Allegra Battistoni; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-12

Review 4.  Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.

Authors:  Stefano Omboni; Ettore Malacco; Jean-Michel Mallion; Paolo Fabrizzi; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-01-17

5.  Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.

Authors:  Prakash Deedwania; Michael Weber; Paul-Egbert Reimitz; George Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-10-25       Impact factor: 3.738

6.  Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats.

Authors:  Hyo-Jeong Lim; Seog-Ki Lee; Dong-Yoon Lim
Journal:  Korean J Physiol Pharmacol       Date:  2013-02-14       Impact factor: 2.016

7.  Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.

Authors:  Yewon Choi; SeungHwan Lee; In-Jin Jang; Kyung-Sang Yu
Journal:  Drug Des Devel Ther       Date:  2018-07-24       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.